A Randomized, Double-Blind, Placebo-Controlled Trial of the Use of Prednisolone as an Adjunct to Treatment in HIV-1—Associated Pleural Tuberculosis

• Published in: The Journal of infectious diseases Vol. 190; no. 5; pp. 869 - 878
• Main Authors: Elliott, Alison M., Luzze, Henry, Quigley, Maria A., Nakiyingi, Jessica S., Kyaligonza, Steven, Namujju, Proscovia B., Ducar, Constance, Ellner, Jerrold J., Whitworth, James A. G., Mugerwa, Roy, Johnson, John L., Okwera, Alphonse
• Format: Journal Article
• Language: English
• Published: United States The University of Chicago Press 01.09.2004; University of Chicago Press; Oxford University Press
• Subjects: Adult; AIDS; AIDS-Related Opportunistic Infections - drug therapy; AIDS-Related Opportunistic Infections - microbiology; AIDS-Related Opportunistic Infections - mortality; Anti-Inflammatory Agents - adverse effects; Anti-Inflammatory Agents - therapeutic use; Antitubercular Agents - therapeutic use; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; HIV; HIV Infections - complications; HIV-1 - drug effects; HIV-1 - physiology; HIV/AIDS; Human immunodeficiency virus 1; Humans; Kaposi sarcoma; Male; Mortality; Mycobacterium tuberculosis; Placebos; Pleural tuberculosis; Prednisolone - adverse effects; Prednisolone - therapeutic use; T lymphocytes; Treatment Outcome; Tuberculosis; Tuberculosis, Pleural - drug therapy; Tuberculosis, Pleural - microbiology; Tuberculosis, Pleural - mortality; Viral Load

Background. Active tuberculosis may accelerate progression of human immunodeficiency virus (HIV) infection by promoting viral replication in activated lymphocytes. Glucocorticoids are used in pleural tuberculosis to reduce inflammation-induced pathology, and their use also might reduce progression o...